{
    "clinical_study": {
        "@rank": "75535", 
        "acronym": "PROBIOC", 
        "arm_group": [
            {
                "arm_group_label": "Lactobacillus reteuri", 
                "arm_group_type": "Experimental", 
                "description": "Dietary Supplement:   Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Other:   Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of the oral administration of\n      Lactobacillus reuteri in treating infantile colic as defined by the Rome III criteria. Forty\n      breastfed infants aged from 29 days to 3 months will be enrolled and blinded randomized to\n      receive orally L.reuteri or placebo. The rate of responders (reduction of daily crying time\n      >50% compared to the baseline) will be assessed at day 7, day 14 and day 21 in both groups.\n      The average daily crying time as well as the associated digestive symptoms will also be\n      analyzed."
        }, 
        "brief_title": "Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infantile Colic", 
        "condition_browse": {
            "mesh_term": "Colic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Exclusively breastfed Infants\n\n          2. Infant aged of 29 days to 3 months\n\n          3. With a diagnosis of infantile colic as defined by the Rome III criteria\n\n          4. Birth at term and eutrophic (weight, height, head circumference)\n\n          5. Apgar score> 7 at 5 minutes\n\n          6. Consent to the study signed by the two parents.\n\n          7. Availability during the study period\n\n        Exclusion Criteria:\n\n          1. Associated severe chronic disease\n\n          2. Acute infectious disease\n\n          3. Personal or family first degree history of allergy to milk proteins\n\n          4. Several infants of the same family from a multiple pregnancy\n\n          5. Infants who received antibiotics one week prior to randomization\n\n          6. Infants who received probiotics one week prior to randomization\n\n          7. Mother who received antibiotics 1 week before randomization\n\n          8. Regular consumption of probiotics by the mother 1 week before randomization\n\n          9. Infants-included in another clinical study\n\n         10. Lack of insurance coverage by the french social security\n\n         11. Non exclusively breastfed infants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887444", 
            "org_study_id": "2013-A00163-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lactobacillus reteuri", 
                "description": "Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.", 
                "intervention_name": "Lactobacillus reuteri DSM17938 probiotic", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pediatric Gastroenterology", 
            "Probiotics", 
            "Lactobacillus reuteri"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "contact": {
                "email": "camille.jung@chicreteil.fr", 
                "last_name": "Camille JUNG, MD PhD", 
                "phone": "+33157022268"
            }, 
            "facility": {
                "address": {
                    "city": "Cr\u00e9teil", 
                    "country": "France", 
                    "zip": "94010"
                }, 
                "name": "CRC CHIC and ACTIV"
            }, 
            "investigator": [
                {
                    "last_name": "Marc Bellaiche, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pediatricians members of the ACTIV association, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Benefit of Using the Lactobacillus Reuteri Probiotic as a Supplement in the Treatment of Newborn Colic", 
        "other_outcome": [
            {
                "measure": "The average duration of crying in the probiotic group compared with the placebo group at D7, D14 and D21.", 
                "safety_issue": "No", 
                "time_frame": "Day 7, 14 and 21"
            }, 
            {
                "measure": "Gastrointestinal symptoms (constipation, diarrhea, flatulence) evaluated at each visit required by the protocol", 
                "safety_issue": "No", 
                "time_frame": "day 7, 14 and 21"
            }
        ], 
        "overall_official": {
            "affiliation": "Robert Debr\u00e9 Hospital", 
            "last_name": "Marc Bellaiche, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The responder rate (infants for whom daily crying time decreases by 50% compared to baseline, D0) at D7 in the probiotic group compared to placebo. The daily crying time will be sound recorded during 24 hours at D0 and D7.and expressed in minutes.", 
            "safety_issue": "No", 
            "time_frame": "day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The responders rates at D14 and D21 in the probiotic group compared to the placebo group.", 
            "safety_issue": "No", 
            "time_frame": "Day 14 and day 21"
        }, 
        "source": "BioGaia AB", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "CRC CHI Creteil France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Association Clinique et therapeutique infantile du Val de Marne ACTIV", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Robert Debr\u00e9 Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "BioGaia AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}